Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib vs Afatinib vs Sequential in HRPC
NCT00706628Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2006
- Primary completion
- Dec 2008
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib, afatinib in prostate cancer (PCa), sponsored by Boehringer Ingelheim. Started Mar 2006; status: completed.
02
Drugs
nintedanibafatinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00706628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00706628.